Moderna beats estimates, lifts 2026 growth to 15%-25% — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Moderna reported third-quarter revenue of $1.31 billion, up 29% from $885.1 million expected, and earnings of 38 cents per share versus an expected loss of $1.25; net income reached $162 million against a $200 million loss a year earlier.
- Moderna raised its full-year 2026 revenue-growth guidance to 15%-25% from up to 10%, citing stronger new products and geographic diversification.
- Moderna's next-generation mRNA Covid vaccine delivered its first full-year impact after receiving U.S. approval in May 2025; seasonal contracts typically established in the first quarter meant its initial launch was small.
- Moderna's stand-alone flu shot, approved in the U.S. in August, will have a limited U.S. launch in 2026 because of its timing.
- Stéphane Bancel said expansion into Canada, the U.K. and Asia helped boost results; international revenue reached $533 million, versus $780 million in the U.S., while cost reductions also contributed to quarterly profit.
- Moderna and Merck unveiled promising late-stage data for an experimental personalized cancer vaccine combined with Keytruda in certain melanoma patients; Moderna shares were battered after a partial data leak days before the planned conference presentation.
- Moderna shares rose roughly 3% in premarket trading Friday and have gained more than 700% this year, largely on optimism about the experimental cancer vaccine.
Why it matters: LSEG's analyst survey listed a $1.25-per-share loss and $885.1 million in revenue, while Moderna delivered 38 cents and $1.31 billion, then lifted 2026 growth guidance to 15%-25%. The $162 million profit, versus a $200 million loss a year earlier, confirms that launches, wider geography and lower costs are already supporting earnings.
Ask SkimNews
